Antioxidant Treatment of Type 2 Diabetes

Early Phase 1

Completed

• Conditions: Type 2 Diabetes
• Interventions: Drug: Placebo; Drug: n-aceylcysteine

• Registration Number: NCT00609102
• Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Brief Summary

This study examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetic subjects.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-01-23
• Study First Submitted QC: 2008-01-23
• Study First Posted: 2008-02-06
• Study Start: 2008-07
• Primary Completion: 2013-09
• Study Completion: 2013-09
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-22
• Last Update Posted: 2014-12-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Subjects with a known diagnosis of type 2 diabetes -

Exclusion Criteria

None, except known intolerance to n-acetylcysteine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
antioxidant drug	n-aceylcysteine	n-acetylcysteine

Primary Outcome Measures

Name	Time	Method
Blood glucose	3 months

Secondary Outcome Measures

Name	Time	Method
HbA1c levels	3 months

Trial Locations

Locations (1)

Pacific Northwest Research Institute; 🇺🇸 Seattle, Washington, United States